These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34911824)

  • 1. Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding.
    Roush D; Blümel J
    PDA J Pharm Sci Technol; 2022; 76(4):323-338. PubMed ID: 34911824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
    Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
    PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies.
    Schwantes A; Specht R; Chen Q
    PDA J Pharm Sci Technol; 2018; 72(5):498-510. PubMed ID: 30030357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
    Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
    PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings of the 2017 Viral Clearance Symposium, Session 1.1: Upstream Mitigation, Part 1-Cell Bank and Bulk Harvest Testing.
    Bolton G; Chen D
    PDA J Pharm Sci Technol; 2018; 72(5):455-460. PubMed ID: 30030351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.
    Reitz S; Schwantes A
    PDA J Pharm Sci Technol; 2022; 76(4):297-305. PubMed ID: 34911829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
    Bolton G
    PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
    De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
    PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
    Roush D; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings of the 2017 Viral Clearance Symposium, Session 3: Resin Lifetime.
    Blümel J; Ma J
    PDA J Pharm Sci Technol; 2018; 72(5):488-497. PubMed ID: 30030358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the 2009 Viral Clearance Symposium.
    Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
    Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral clearance capability of monoclonal antibody purification.
    Cai K; Anderson J; Utiger E; Ferreira G
    Biologicals; 2024 Feb; 85():101751. PubMed ID: 38387156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of the 2019 Viral Clearance Symposium, Session 2: New Modalities in Chromatography and Adsorptive Filters.
    Specht R; Schwantes A
    PDA J Pharm Sci Technol; 2022; 76(4):306-314. PubMed ID: 34911828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
    O'Donnell S; Bolton G
    PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proceedings of the 2019 Viral Clearance Symposium, Session 3: Continuous Processing.
    Lute S; Specht R
    PDA J Pharm Sci Technol; 2022; 76(4):315-322. PubMed ID: 34911830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings of the 2017 Viral Clearance Symposium.
    Hepbildikler S; Nothelfer F
    PDA J Pharm Sci Technol; 2018; 72(5):453-454. PubMed ID: 30030350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings of the 2019 Viral Clearance Symposium, Session 7: Cell Banks and U.S. Pharmacopeia.
    O'Donnell S
    PDA J Pharm Sci Technol; 2022; 76(4):358-361. PubMed ID: 34911823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings of the 2017 Viral Clearance Symposium: Conclusion.
    Hepbildikler S; Johnson S; Bluemel J
    PDA J Pharm Sci Technol; 2018; 72(5):525-530. PubMed ID: 30030353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
    Ma J; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.